#43: Gene-Editing - The Next Game-Changing Technology?

with Tilmann Buerckstuemmer and Thomas Moser, Aelian Biotechnology

Investing in Life Science

In 2021 I thought it is a smart idea to shine more light on life science companies, as more and more people and institutions got interested in investments in the pharmaceutical industry.

The life science b2b value chain is one of the most complex ones. Without deep insight into science, it is challenging to judge from the outside…

This episode is for paying subscribers